Quarterly ResultMay 15, 2026, 08:33 AM
Moleculin Q1 Net Loss $(12.8)M; MIRACLE Trial Shows 40% Remission Rate
AI Summary
Moleculin Biotech reported its first quarter 2026 financial results and provided a clinical update on its pivotal MIRACLE trial for relapsed/refractory AML. The company announced encouraging early blinded results from the MIRACLE trial, showing a 40% composite complete remission rate at both the 30 and 45 subject marks, with the first interim unblinding expected in June 2026. Financially, Moleculin reported a net loss of $(12.8) million for the quarter and secured approximately $8.3 million in gross proceeds from financing transactions, extending its cash runway into Q3 2026.
Key Highlights
- MIRACLE trial showed 40% composite complete remission rate in early blinded results (30 & 45 subjects).
- First interim unblinding of 45-subject data in MIRACLE trial expected in June 2026.
- Net loss for Q1 2026 was $(12.8) million, compared to $(5.9) million in Q1 2025.
- Research and development expenses increased to $5.4 million in Q1 2026 from $3.4 million in Q1 2025.
- Secured approximately $8.3 million in gross proceeds from financing transactions in Q1 2026.
- Cash and cash equivalents totaled $10.3 million as of March 31, 2026.
- Current cash resources are expected to support operations into Q3 2026.
Price Impact
More from MBRX